Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
MEDICINE	O
Allergies:	O
Sulfa	O
(Sulfonamide	O
Antibiotics)	O
/	O
Percocet	O
/	O
Codeine	O
/	O
Penicillins	O
Attending:	O
___.	O
Chief	O
Complaint:	O
epigastric	O
pain,	O
vomiting,	O
altered	B-Delirium
mental	B-Delirium
status	B-Delirium
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
none	O
History	O
of	O
Present	O
Illness:	O
___	O
y/o	O
F	O
with	O
PMH	O
of	O
CVA,	O
HTN,	O
COPD	O
and	O
mild	O
dementia	B-Dementia
who	O
presented	O
with	O
altered	B-Delirium
mental	B-Delirium
status	B-Delirium
and	O
general	O
weakness	O
since	O
day	O
of	O
admission.	O
A	O
day	O
prior	O
to	O
her	O
admission	O
complained	O
of	O
epigastric	O
pain	O
and	O
nausea	O
and	O
had	O
multiple	O
episodes	O
of	O
vomiting	B-Upper_gastrointestinal_haemorrhage
of	O
greenish	O
stomach	O
content	O
without	O
blood.	B-Upper_gastrointestinal_haemorrhage
There	O
was	O
no	O
diarrhea,	O
no	O
fever	O
or	O
chills,	O
no	O
SOB,	O
chest	O
pain	O
or	O
other	O
complaints.	O
No	O
history	O
of	O
consumption	O
of	O
suspect	O
food	O
or	O
contact	O
with	O
ill	O
persons.	O
On	O
the	O
day	O
of	O
admission	O
no	O
longer	O
had	O
any	O
pain	O
or	O
GI	O
complaints	O
but	O
her	O
daughter	O
noticed	O
significant	O
mental	B-Delirium
status	B-Delirium
change	B-Delirium
with	O
confusion	B-Delirium
and	O
disorientation	B-Delirium
and	O
thus	O
decided	O
to	O
go	O
the	O
ER.	O
In	O
the	O
ED,	O
initial	O
vs	O
were:	O
97.7	O
110	O
117/68	O
17	O
100.	O
Had	O
abdominal	O
US	O
and	O
CT	O
which	O
demonstrated	O
cholelithiasis,	O
gallbladder	O
wall	O
edema,	O
pericholecystic	O
fluid	O
which	O
was	O
interpreted	O
as	O
not	O
exclusive	O
of	O
early	O
acute	O
cholecystitis.	O
Patient	O
was	O
given	O
unasyn	O
3gm	O
IV	O
and	O
1L	O
NS	O
and	O
was	O
sent	O
for	O
further	O
managment	O
to	O
the	O
floor.	O
Past	O
Medical	O
History:	O
.	O
-	O
COPD,	O
no	O
oxygen	O
at	O
home.	O
Recent	O
admission	O
___	O
for	O
flare	O
treated	O
w/	O
prednisone,	O
nebs	O
and	O
azithromycin.	O
.	O
-	O
___	O
s/p	O
2	O
lobectomies	O
___	O
yrs	O
ago	O
with	O
complete	O
excision,	O
no	O
chemo	O
or	O
radiation.	O
Has	O
chest	O
CT	O
from	O
___	O
which	O
prompted	O
recomendation	O
for	O
considering	O
another	O
bronchoscopy	O
with	O
biopsy.	O
.	O
-	O
HTN	O
-	O
hypercholesterolemia	O
-	O
CVA	O
___	O
(PFO)	O
-	O
H1N1	O
___	O
-	O
Left	O
ankle	O
fracture	O
___	O
-	O
s/p	O
back	O
surgery	O
-	O
s/p	O
hysterectomy	O
Allergies:	O
Sulfa	O
-	O
hives	O
PCN	O
-	O
hives	O
Social	O
History:	O
___	O
Family	O
History:	O
father	O
died	O
of	O
MI	O
at	O
age	O
___.	O
Physical	O
Exam:	O
Physical	O
Exam:	O
Vitals:	O
T:	O
99.5	O
BP:	O
110/69	O
P:	O
110	O
R:	O
30	O
O2:	O
99%RA	O
General:	O
A+O	O
X	O
2	O
(not	O
to	O
time).	O
No	O
acute	O
distress	O
but	O
patient	O
considerably	O
tachypneic	O
___	O
without	O
over	O
respiratory	O
distress,	O
daughter	O
says	O
this	O
is	O
baseline.	O
HEENT:	O
Sclera	O
anicteric,	O
MMM,	O
small	O
petechiae	O
under	O
anterior	O
tongue	O
Neck:	O
supple,	O
JVD	O
++	O
with	O
HJ	O
reflux	O
+	O
Lungs:	O
surgical	O
scar	O
over	O
right	O
upper	O
posterior	O
chest.	O
Clear	O
to	O
auscultation	O
bilaterally,	O
no	O
wheezes,	O
rales,	O
ronchi	O
CV:	O
Rapid	O
Regular	O
rate	O
and	O
rhythm,	O
normal	O
S1	O
+	O
S2,	O
no	O
murmurs,	O
rubs,	O
gallops	O
Abdomen:	O
soft,	O
non-tender,	O
non-distended,	O
BS	O
+1,	O
no	O
rebound	O
tenderness	O
or	O
guarding,	O
no	O
organomegaly	O
Ext:	O
warm	O
and	O
well	O
perfused,	O
1+	O
pulses,	O
no	O
edema	O
or	O
signs	O
of	O
DVT	O
Pertinent	O
Results:	O
Admission	O
labs:	O
___	O
09:15AM	O
BLOOD	O
WBC-20.6*#	O
RBC-4.93#	O
Hgb-15.0#	O
Hct-45.8#	O
MCV-93	O
MCH-30.4	O
MCHC-32.8	O
RDW-12.8	O
Plt	O
___	O
___	O
09:15AM	O
BLOOD	O
Neuts-84*	O
Bands-0	O
Lymphs-8*	O
Monos-6	O
Eos-0	O
Baso-0	O
Atyps-2*	O
___	O
Myelos-0	O
___	O
09:15AM	O
BLOOD	O
Glucose-106*	O
UreaN-12	O
Creat-1.0	O
Na-138	O
K-4.5	O
Cl-99	O
HCO3-25	O
AnGap-15	O
___	O
09:15AM	O
BLOOD	O
ALT-30	O
AST-82*	O
LD(LDH)-474*	O
CK(CPK)-244*	O
AlkPhos-64	O
TotBili-0.5	O
___	O
09:15AM	O
BLOOD	O
Lipase-23	O
___	O
09:15AM	O
BLOOD	O
CK-MB-15*	O
MB	O
Indx-6.1*	O
cTropnT-0.62*	O
___	O
09:15AM	O
BLOOD	O
Albumin-3.7	O
Calcium-8.9	O
Phos-2.9	O
Mg-2.1	O
___	O
11:30AM	O
URINE	O
Blood-NEG	O
Nitrite-NEG	O
Protein-NEG	O
Glucose-NEG	O
Ketone-TR	O
Bilirub-NEG	O
Urobiln-NEG	O
pH-7.0	O
Leuks-NEG	O
.	O
Discharge	O
labs:	O
___	O
WBC-7.9	O
Hgb-11.7*	O
Hct-33.6*	O
Plt	O
___	O
.	O
Micro:	O
___	O
Urine	O
cultur:	O
no	O
growth	O
___	O
Blood	O
cultures:	O
pending***	O
.	O
CXR	O
___:	O
The	O
cardiac	O
size	O
is	O
normal.	O
The	O
mediastinal	O
contours	O
demonstrate	O
a	O
markedly	O
tortuous	O
aorta	O
with	O
calcified	O
atherosclerotic	O
disease	O
at	O
the	O
knob	O
and	O
descending	O
aorta.	O
Clips	O
in	O
the	O
right	O
hilar	O
region	O
are	O
most	O
consistent	O
with	O
the	O
patient's	O
known	O
history	O
of	O
prior	O
partial	O
resection	O
and	O
deformity	O
of	O
the	O
right	O
posterior	O
fifth	O
rib	O
is	O
also	O
consistent	O
with	O
prior	O
thoracotomy.	O
The	O
lungs	O
are	O
clear.	O
There	O
is	O
no	O
large	O
pleural	O
effusion	O
or	O
pneumothorax.	O
Again	O
is	O
noted	O
an	O
unchanged	O
wedge-deformity	O
of	O
a	O
lower	O
thoracic	O
vertebral	O
body,	O
unchanged	O
since	O
___.	O
IMPRESSION:	O
No	O
acute	O
cardiopulmonary	O
process.	O
.	O
CT	O
___	O
Abd/Pelv:	O
1.	O
Distended	O
hyperemic	O
gallbladder	O
with	O
pericholecystic	O
fluid	O
concerning	O
for	O
acute	O
cholecystitis;	O
right	O
upper	O
quadrant	O
ultrasound	O
is	O
recommended.	O
2.	O
Dense	O
structure	O
in	O
the	O
region	O
of	O
the	O
gallbladder	O
neck/neighboring	O
duodenum	O
may	O
represent	O
an	O
impacted	O
gallstone,	O
varix,	O
or	O
enhancing	O
soft	O
tissue	O
nodule.	O
Further	O
attention	O
will	O
be	O
paid	O
on	O
ensuing	O
ultrasound.	O
.	O
RUQ	O
ultrasound	O
___:	O
Cholelithiasis	O
with	O
gallbladder	O
wall	O
thickening	O
and	O
small	O
amount	O
of	O
pericholecystic	O
fluid.	O
Although	O
no	O
sonographic	O
___	O
sign,	O
findings	O
raise	O
concern	O
for	O
early	O
acute	O
cholecystitis	O
in	O
the	O
appropriate	O
clinical	O
setting.	O
.	O
CT	O
head	O
___:	O
No	O
acute	O
intracranial	O
process;	O
chronic	O
small	O
vessel	O
ischemic	O
disease	O
and	O
atrophic	O
changes.	O
.	O
EKG	O
___:	O
sinus	O
tachycardia	O
to	O
110,	O
left	O
axis	O
wnl,	O
flattened	O
T-waves	O
II,	O
III,	O
AVF,	O
TWI	O
V4-V6	O
with	O
minimal	O
ST	O
elevations	O
<	O
0.5mm	O
V5-V6,	O
low	O
QRS	O
voltage.	O
ST-T	O
changes	O
are	O
new	O
compared	O
to	O
___	O
tracing.	O
.	O
Echocardiography	O
___:	O
The	O
left	O
atrium	O
is	O
elongated.	O
Left	O
ventricular	O
wall	O
thicknesses	O
and	O
cavity	O
size	O
are	O
normal.	O
There	O
is	O
mild	O
to	O
moderate	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
severe	O
hypokinesis	O
of	O
the	O
inferolateral	O
wall	O
and	O
distal	O
anterolateral	O
wall.	O
The	O
remaining	O
segments	O
contract	O
normally	O
(LVEF	O
=	O
___.	O
The	O
estimated	O
cardiac	O
index	O
is	O
normal	O
(>=2.5L/min/m2).	O
Tissue	O
Doppler	O
imaging	O
suggests	O
an	O
increased	O
left	O
ventricular	O
filling	O
pressure	O
(PCWP>18mmHg).	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal.	O
The	O
ascending	O
aorta	O
is	O
mildly	O
dilated.	O
The	O
aortic	O
valve	O
leaflets	O
(3)	O
are	O
mildly	O
thickened	O
but	O
aortic	O
stenosis	O
is	O
not	O
present.	O
Mild	O
(1+)	O
aortic	O
regurgitation	O
is	O
seen.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened.	O
Mild	O
(1+)	O
mitral	O
regurgitation	O
is	O
seen.	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension.	O
There	O
is	O
an	O
anterior	O
space	O
which	O
most	O
likely	O
represents	O
a	O
prominent	O
fat	O
pad.	O
IMPRESSION:	O
Technically	O
suboptimal	O
study.	O
Normal	O
cavity	O
size	O
with	O
regional	O
systolic	O
dysfunction	O
suggestive	O
of	O
multivessel	O
CAD.	O
Increased	O
PCWP.	O
Mild	O
aortic	O
regurgitation.	O
Pulmonary	O
artery	O
systolic	O
hypertension.	O
Mild	O
mitral	O
regurgitation.	O
Compared	O
with	O
the	O
prior	O
study	O
(images	O
reviewed)	O
of	O
___,	O
the	O
findings	O
are	O
similar,	O
and	O
better	O
defined	O
on	O
the	O
current	O
study.	O
Brief	O
Hospital	O
Course:	O
Mrs.	O
___	O
is	O
an	O
___	O
y/o	O
woman	O
with	O
PMH	O
of	O
CVA,	O
HTN,	O
COPD	O
and	O
mild	O
dementia	B-Dementia
who	O
presents	O
with	O
AMS	B-Delirium
one	O
day	O
after	O
transient	O
complaints	O
of	O
n/v/abdominal	O
pain	O
and	O
was	O
found	O
to	O
have	O
an	O
NSTEMI.	O
.	O
#	O
NSTEMI:	O
Mrs	O
___	O
was	O
found	O
to	O
have	O
an	O
inferior-lateral	O
NSTEMI	O
by	O
EKG	O
changes	O
and	O
positive	O
enzymes	O
(see	O
pertinent	O
results	O
above).	O
She	O
was	O
thought	O
to	O
have	O
suffered	O
the	O
MI	O
a	O
day	O
prior	O
to	O
her	O
presentation;	O
her	O
symptoms	O
of	O
epigastric	O
pain	O
and	O
vomiting	O
were	O
probably	O
angina	O
aquivalent.	O
This	O
was	O
supported	O
by	O
the	O
finding	O
on	O
presentation	O
of	O
later	O
stage	O
enzyme	O
elevations	O
including	O
LDH	O
and	O
AST.	O
The	O
minimal	O
ST	O
elevation	O
in	O
V5-V6	O
were	O
not	O
thought	O
to	O
not	O
qualifty	O
this	O
as	O
an	O
STEMI.	O
The	O
patient	O
was	O
stable	O
hemodynamically	O
and	O
well	O
saturated	O
on	O
room	O
air	O
throughout	O
her	O
admission	O
w/o	O
overt	O
signs	O
of	O
heart	O
failure,	O
but	O
her	O
tachycardia	O
and	O
increased	O
JVD	O
may	O
have	O
hinted	O
to	O
some	O
hemodynamic	O
effects	O
of	O
her	O
MI.	O
Echocardiography	O
showed	O
normal	O
cavity	O
size	O
with	O
regional	O
systolic	O
dysfunction	O
(EF	O
35%)	O
suggestive	O
of	O
multivessel	O
CAD;	O
also	O
increased	O
PCWP,	O
mild	O
aortic	O
and	O
mitral	O
regurgitation,	O
and	O
pulmonary	O
artery	O
systolic	O
hypertension.	O
Cardiology	O
was	O
consulted	O
and	O
recommended	O
conservative	O
managment,	O
as	O
the	O
acute	O
ischemic	O
event	O
was	O
thought	O
to	O
have	O
resolved	O
prior	O
to	O
presentation	O
rendering	O
reperfusional	O
intervention	O
without	O
significant	O
short	O
term	O
or	O
long	O
term	O
benefit.	O
Mrs.	O
___	O
was	O
started	O
on	O
Aspirin	O
and	O
Plavix	O
in	O
place	O
of	O
Aggrenox-aspirin	O
combination,	O
and	O
she	O
was	O
treated	O
with	O
48	O
hours	O
of	O
IV	O
heparin.	O
She	O
was	O
continued	O
on	O
her	O
ACE-I.	O
A	O
beta	O
blocker	O
was	O
started,	O
and	O
her	O
statin	O
was	O
increased	O
to	O
high-dose.	O
Her	O
tachycardia	O
resolved	O
and	O
she	O
continued	O
to	O
be	O
asymptomatic	O
and	O
clinically	O
stable	O
throughout	O
her	O
course.	O
.	O
#	O
Low-normal	O
blood	O
pressure:	O
Patient	O
reports	O
low-normal	O
BP	O
at	O
baseline,	O
and	O
her	O
SBPs	O
were	O
stably	O
in	O
the	O
___	O
with	O
the	O
addition	O
of	O
the	O
beta	O
blocker;	O
she	O
was	O
not	O
orthostatic.	O
Her	O
blood	O
pressure	O
should	O
continued	O
to	O
be	O
monitored	O
with	O
adjustment	O
of	O
antihypertensives	O
as	O
needed.	O
.	O
#	O
Cholelithiasis:	O
Upon	O
presentation	O
US	O
+	O
CT	O
of	O
the	O
abdomen	O
demonstarted	O
cholelithiasis	O
as	O
well	O
as	O
raised	O
the	O
specter	O
of	O
a	O
possible	O
developing	O
acute	O
cholecystitis	O
given	O
leukocytosis.	O
She	O
recieved	O
1	O
dose	O
of	O
Unasyn	O
in	O
the	O
ED	O
but	O
this	O
was	O
discontinued	O
on	O
the	O
floor.	O
She	O
remained	O
afebrile	O
and	O
asymptomatic;	O
her	O
abdominal	O
exams	O
were	O
benign	O
throughout	O
her	O
hospital	O
course,	O
and	O
her	O
LFTs	O
normalized.	O
Could	O
consider	O
surgical	O
evaluation	O
in	O
the	O
outpatient	O
setting	O
for	O
prophylactic	O
cholecystectomy.	O
.	O
#	O
Leukocystosis:	O
Mrs	O
___	O
was	O
afebrile	O
at	O
and	O
throughout	O
presentation	O
and	O
had	O
a	O
significant	O
leukocytosis	O
which	O
later	O
resolved	O
and	O
was	O
thought	O
to	O
be	O
secondary	O
to	O
her	O
MI.	O
Micro	O
culture	O
has	O
been	O
negative	O
to	O
date.	O
.	O
#	O
COPD:	O
Mrs.	O
___	O
has	O
baseline	O
COPD	O
and	O
developed	O
some	O
wheezing	O
during	O
this	O
admission.	O
This	O
may	O
have	O
been	O
related	O
to	O
starting	O
BB	O
therapy.	O
She	O
has	O
baseline	O
tachypnea,	O
her	O
respiratory	O
rates	O
were	O
in	O
the	O
___	O
on	O
admission	O
and	O
came	O
down	O
to	O
the	O
low	O
___	O
on	O
discharge.	O
She	O
had	O
no	O
cough	O
or	O
fever	O
and	O
responded	O
well	O
to	O
nebulized	O
bronchodialators.	O
.	O
#	O
Anemia:	O
Hct	O
downtrended	O
from	O
45.8	O
to	O
33.6	O
but	O
remained	O
stable	O
in	O
the	O
low	O
___	O
on	O
discharge.	O
The	O
initial	O
levels	O
may	O
have	O
been	O
falsely	O
elevated	O
due	O
to	O
hemoconcentration	O
in	O
the	O
setting	O
of	O
dehydration	O
as	O
she	O
also	O
had	O
a	O
mild	O
rise	O
in	O
Cr	O
from	O
0.9	O
to	O
1.2.	O
Her	O
stool	O
guaiacs	O
were	O
negative	O
and	O
she	O
had	O
no	O
other	O
overt	O
bleeding.	O
Her	O
Hct	O
should	O
continue	O
to	O
be	O
repeated	O
post-discharge	O
and	O
further	O
outpatient	O
work-up	O
done	O
for	O
anemia	O
as	O
needed.	O
.	O
#	O
Acute	O
renal	O
failure:	O
Creatinine	O
uptrended	O
from	O
0.9	O
on	O
presentation	O
to	O
1.2.	O
Her	O
FeNa	O
and	O
FEUrea	O
suggested	O
a	O
prerenal	O
etiology	O
and	O
Cr	O
normalized	O
with	O
encouragement	O
of	O
po	O
fluid	O
intake.	O
.	O
#	O
Pending	O
Labs:	O
___	O
Blood	O
cultures	O
x	O
2	O
****	O
Medications	O
on	O
Admission:	O
-home	O
02	O
2L	O
at	O
night	O
and	O
4L	O
with	O
ambulation	O
-Nortriptyline	O
10	O
mg	O
Capsule	O
Sig:	O
One	O
(1)	O
Capsule	O
PO	O
HS	O
(at	O
bedtime).	O
-Lisinopril	O
5	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
-Simvastatin	O
40	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
-Mirtazapine	O
15	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
HS	O
(at	O
bedtime).	O
-Pregabalin	O
(Lyrica)	O
100	O
mg	O
Capsule	O
Sig:	O
One	O
(1)	O
Capsule	O
PO	O
TID	O
(3	O
times	O
a	O
day).	O
-Folic	O
Acid	O
1	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
-Dipyridamole-Aspirin	O
(Aggrenox)	O
___	O
mg	O
Cap,	O
Multiphasic	O
Release	O
12	O
hr	O
Sig:	O
One	O
(1)	O
Cap	O
PO	O
BID	O
(2	O
times	O
a	O
day).	O
-DuoNeb	O
0.5-2.5	O
mg/3	O
mL	O
Solution	O
for	O
Nebulization	O
Sig:	O
One	O
(1)	O
neb	O
Inhalation	O
every	O
four	O
(4)	O
hours	O
as	O
needed	O
for	O
shortness	O
of	O
breath	O
or	O
wheezing.	O
-Pyridoxine	O
25	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY.	O
-Ranitidine	O
HCl	O
300	O
mg	O
Capsule	O
Sig:	O
One	O
(1)	O
Capsule	O
PO	O
BID	O
(2	O
times	O
a	O
day).	O
Discharge	O
Medications:	O
1.	O
Nortriptyline	O
10	O
mg	O
Capsule	O
Sig:	O
One	O
(1)	O
Capsule	O
PO	O
HS	O
(at	O
bedtime).	O
2.	O
Mirtazapine	O
15	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
HS	O
(at	O
bedtime).	O
3.	O
Pregabalin	O
100	O
mg	O
Capsule	O
Sig:	O
One	O
(1)	O
Capsule	O
PO	O
TID	O
(3	O
times	O
a	O
day).	O
4.	O
Folic	O
Acid	O
1	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
5.	O
Lisinopril	O
5	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
6.	O
DuoNeb	O
0.5	O
mg-3	O
mg(2.5	O
mg	O
base)/3	O
mL	O
Solution	O
for	O
Nebulization	O
Sig:	O
One	O
(1)	O
Inhalation	O
every	O
___	O
hours	O
as	O
needed	O
for	O
shortness	O
of	O
breath	O
or	O
wheezing.	O
7.	O
Pyridoxine	O
25	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
once	O
a	O
day.	O
8.	O
Metoprolol	O
Tartrate	O
25	O
mg	O
Tablet	O
Sig:	O
0.5	O
Tablet	O
PO	O
BID	O
(2	O
times	O
a	O
day).	O
9.	O
Aspirin	O
325	O
mg	O
Tablet,	O
Delayed	O
Release	O
(E.C.)	O
Sig:	O
One	O
(1)	O
Tablet,	O
Delayed	O
Release	O
(E.C.)	O
PO	O
once	O
a	O
day.	O
10.	O
Clopidogrel	O
75	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
once	O
a	O
day.	O
11.	O
Simvastatin	O
80	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
once	O
a	O
day.	O
12.	O
Ranitidine	O
HCl	O
150	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
twice	O
a	O
day.	O
Discharge	O
Disposition:	O
Extended	O
Care	O
Facility:	O
___	O
___	O
Diagnosis:	O
Non	O
ST	O
elevation	O
Myocardial	O
Infarction	O
Discharge	O
Condition:	O
Mental	O
Status:	O
Confused	B-Delirium
-	O
sometimes.	O
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Mobile_with_assistance
-	O
requires	O
assistance	B-Mobile_with_assistance
or	O
aid	B-Mobile_with_aid
(walker	O
or	O
cane).	O
Discharge	O
Instructions:	O
You	O
were	O
admitted	O
because	O
of	O
abdominal	O
pain	O
and	O
vomiting	O
the	O
day	O
prior	O
to	O
your	O
admission.	O
You	O
were	O
found	O
to	O
have	O
had	O
a	O
myocardial	O
infarction	O
or	O
heart	O
attack	O
which	O
is	O
what	O
happens	O
when	O
the	O
blood	O
flow	O
to	O
part	O
of	O
your	O
heart	O
muscle	O
is	O
obstructed	O
for	O
a	O
period	O
of	O
time	O
by	O
a	O
blood	O
clot	O
causing	O
damage	O
to	O
heart	O
muscle	O
cells.	O
You	O
were	O
treated	O
with	O
medication	O
to	O
allow	O
the	O
blood	O
clot	O
to	O
dissipate	O
and	O
improve	O
the	O
condition	O
of	O
your	O
heart	O
muscle.	O
You	O
do	O
have	O
some	O
decrease	O
in	O
your	O
heart	O
pump	O
function,	O
and	O
this	O
will	O
need	O
to	O
be	O
followed	O
up	O
with	O
a	O
cardiologist	O
as	O
an	O
outpatient.	O
.	O
The	O
following	O
changes	O
were	O
made	O
to	O
your	O
medications:	O
.	O
1.	O
Aggrenox-aspirin	O
capsule	O
was	O
discontinued.	O
2.	O
Aspirin	O
325mg	O
tablet	O
was	O
started.	O
Take	O
1	O
tablet	O
once	O
daily	O
to	O
reduce	O
the	O
risk	O
of	O
heart	O
attacks	O
and	O
stroke.	O
3.	O
Plavix	O
75mg	O
tablet	O
was	O
started.	O
You	O
should	O
take	O
one	O
tablet	O
once	O
daily	O
to	O
reduce	O
the	O
risk	O
of	O
heart	O
attack.	O
4.	O
Simvastatin	O
40mg	O
tablet	O
was	O
changed	O
to	O
Simvastatin	O
80mg	O
tablet,	O
you	O
should	O
take	O
1	O
tablet	O
once	O
daily	O
to	O
control	O
your	O
cholesterol	O
and	O
reduce	O
your	O
risk	O
of	O
heart	O
attack.	O
5.	O
Rantidine	O
300mg	O
tablet	O
was	O
changed	O
to	O
Ranitidine	O
150mg	O
tablet	O
which	O
is	O
a	O
dose	O
better	O
___	O
to	O
your	O
renal	O
functions.	O
Take	O
one	O
tablet	O
twice	O
daily	O
to	O
lower	O
acidity	O
in	O
your	O
stomach.	O
Followup	O
Instructions:	O
___	O

